Effects of Xuezhikang vs. Pravastatin on Triglyceride Level in Patients with Type 2 Diabetes Mellitus and Dyslipidemia: A Research Protocol for a Randomized Controlled Study

Effects of Xuezhikang vs. Pravastatin on Triglyceride Level in Patients with Type 2 Diabetes Mellitus and Dyslipidemia: A Research Protocol for a Randomized Controlled Study | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Research Effects of Xuezhikang vs. Pravastatin on Triglyceride Level in Patients with Type 2 Diabetes Mellitus and Dyslipidemia: A Research Protocol for a Randomized Controlled Study Jin Xu, Xiao Du, Shilan Zhang, Qunyan Xiang, Liling Guo, Liyuan Zhu, and 6 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-871652/v1 This work is licensed under a CC BY 4.0 License Status: Posted Version 1 posted You are reading this latest preprint version Abstract Background: Diabetes often accompanies with increase in triglyceride(TG) as well as small dense low density lipoprotein(sdLDL). Statins are difficult to completely correct this dyslipidemia. Xuezhikang, an extract of cholestin, is better than some statins in reducing TG. Under the condition of the similar decrease in LDL-cholesterol (LDL-C), it is not clear whether there is any difference in the effect of XZK and statins on TG reduction in patients with Type 2 DM(T2DM). Methods: An open-label multicenter study is planned to estimate the effects of Xuezhikang(1.2 g/d) and pravastatin(20 mg/d) on TG level and other blood lipids in T2DM patients with dyslipidemia and moderate to high risk of cardiovascular diseases. A total of 114 patients will be enrolled and randomly assigned (1:1 ratio) to accept Xuezhikang or pravastatin therapy for 6 weeks. The primary outcome measure is the change in fasting TG level after 6 weeks. The changes in other fasting lipids and postprandial lipids at 1, 2, 4 h after a nutritious breakfast will also be explored. The planned duration for enrollment is between November 2021 and December 2022. Conclusion: This study will evaluate the effect of 6-week treatment of Xuezhikang(1.2 g/d) and pravastatin(20 mg/d) on fasting TG level and other blood lipids in T2DM patients with dyslipidemia, which may provide a more optimized schedule for lipid control in patients with diabetes and dyslipidemia in primary prevention. Cardiac & Cardiovascular Systems Endocrinology & Metabolism diabetes triglyceride dyslipidemia Xuezhikang Cardiovascular risk Figures Figure 1 Full Text Cite Share Download PDF Status: Posted Version 1 posted You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-871652","acceptedTermsAndConditions":true,"allowDirectSubmit":true,"archivedVersions":[],"articleType":"Research","associatedPublications":[],"authors":[{"id":50714016,"identity":"23930e69-268d-49c9-bbe6-8e3702fdea87","order_by":0,"name":"Jin Xu","email":"","orcid":"","institution":"Second Xiangya Hospital","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Jin","middleName":"","lastName":"Xu","suffix":""},{"id":50714017,"identity":"548bb5e0-fc4c-4859-899c-b7532f944acc","order_by":1,"name":"Xiao Du","email":"","orcid":"","institution":"Second Xiangya Hospital","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Xiao","middleName":"","lastName":"Du","suffix":""},{"id":50714018,"identity":"530d8920-7515-4b56-bfbb-d51cc3600165","order_by":2,"name":"Shilan Zhang","email":"","orcid":"","institution":"Second Xiangya Hospital","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Shilan","middleName":"","lastName":"Zhang","suffix":""},{"id":50714019,"identity":"fddabe8e-fd18-4631-9262-0c06a21da54d","order_by":3,"name":"Qunyan Xiang","email":"","orcid":"","institution":"Second Xiangya Hospital","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Qunyan","middleName":"","lastName":"Xiang","suffix":""},{"id":50714020,"identity":"745e4793-b820-4e7b-9162-00e3ead59fc5","order_by":4,"name":"Liling Guo","email":"","orcid":"","institution":"Second Xiangya Hospital","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Liling","middleName":"","lastName":"Guo","suffix":""},{"id":50714021,"identity":"922f6438-671a-4e28-becd-0d06d1b494ef","order_by":5,"name":"Liyuan Zhu","email":"","orcid":"","institution":"Second Xiangya Hospital","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Liyuan","middleName":"","lastName":"Zhu","suffix":""},{"id":50714022,"identity":"33f1c378-132a-4e1c-96e8-0aa32856e767","order_by":6,"name":"Yangrong Tan","email":"","orcid":"","institution":"Second Xiangya Hospital","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Yangrong","middleName":"","lastName":"Tan","suffix":""},{"id":50714023,"identity":"29a2f876-55bf-478f-98c3-6f9346b4e8fe","order_by":7,"name":"Yan Fu","email":"","orcid":"","institution":"Second Xiangya Hospital","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Yan","middleName":"","lastName":"Fu","suffix":""},{"id":50714024,"identity":"fc911e46-a597-4d46-baef-c543d1d35f16","order_by":8,"name":"Yingying Xie","email":"","orcid":"","institution":"Second Xiangya Hospital","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Yingying","middleName":"","lastName":"Xie","suffix":""},{"id":50714025,"identity":"4ca78384-a0fb-4752-bc6d-b6fffecf7999","order_by":9,"name":"Miao Zhang","email":"","orcid":"","institution":"Second Xiangya Hospital","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Miao","middleName":"","lastName":"Zhang","suffix":""},{"id":50714026,"identity":"8b7388e8-9235-4a62-a8be-57e278ea098c","order_by":10,"name":"Tie Wen","email":"","orcid":"","institution":"Second Xiangya Hospital","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Tie","middleName":"","lastName":"Wen","suffix":""},{"id":50714027,"identity":"6e51e14e-aa9c-443e-a14c-3b6ba9c77da9","order_by":11,"name":"Ling Liu","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAAA3UlEQVRIiWNgGAWjYBAC9gbmhgMMBRIgFliAsYGQFp4DjEAtBhIgFglaGBgMgCyJBGK1sDc2HuYxsMiTj3z8+DMPg43shgPMzx7g1cJzsAGoRaLY8HaamTQPQ5rxhgNs5gb4tNhLJIK1JG6cncPGzMNwOHHDAR42Cby2yD+Eapl5hhnosP9EaJFghGiZL8HDAHTYASK08CQ2HJwD1LKBJ81Mco5BsvHMw2xm+LWwHz784U1FXeL89sOPgQw72b7jzc/waoEDgwNgEoiZiVIPBPINxKocBaNgFIyCEQcArs9GmPRZkUcAAAAASUVORK5CYII=","orcid":"https://orcid.org/0000-0001-6979-701X","institution":"Second Xiangya Hospital","correspondingAuthor":true,"submittingAuthor":false,"prefix":"","firstName":"Ling","middleName":"","lastName":"Liu","suffix":""}],"badges":[],"createdAt":"2021-09-03 10:29:33","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-871652/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-871652/v1","draftVersion":[],"editorialEvents":[],"editorialNote":"","failedWorkflow":false,"files":[{"id":13369116,"identity":"c7ec2006-5e9a-448f-ba46-126063c78f1c","added_by":"auto","created_at":"2021-09-14 16:18:46","extension":"png","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":116756,"visible":true,"origin":"","legend":"Study design.","description":"","filename":"1.png","url":"https://assets-eu.researchsquare.com/files/rs-871652/v1/fee0f4452702713ee1001042.png"},{"id":13679106,"identity":"c5c6d25c-b969-432c-b456-0d3a5597a1bb","added_by":"auto","created_at":"2021-09-17 11:42:12","extension":"pdf","order_by":1,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":348869,"visible":true,"origin":"","legend":"","description":"","filename":"20210831.pdf","url":"https://assets-eu.researchsquare.com/files/rs-871652/v1_covered.pdf"},{"id":13369117,"identity":"369a099b-5d85-4867-9c1a-ff7276388787","added_by":"auto","created_at":"2021-09-14 16:18:54","extension":"pdf","order_by":1,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":345244,"visible":true,"origin":"","legend":"","description":"","filename":"20210831.pdf","url":"https://assets-eu.researchsquare.com/files/rs-871652/v1_covered.pdf"}],"financialInterests":"","formattedTitle":"\u003cp\u003eEffects of Xuezhikang vs. Pravastatin on Triglyceride Level in Patients with Type 2 Diabetes Mellitus and Dyslipidemia: A Research Protocol for a Randomized Controlled Study\u003c/p\u003e","fulltext":[{"header":"Full Text","content":"This preprint is available for \u003ca href='/article/rs-871652/latest.pdf' target='_blank'\u003edownload as a PDF\u003c/a\u003e."}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":false,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":true,"highlight":"","institution":"","isAcceptedByJournal":false,"isAuthorSuppliedPdf":true,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true},"keywords":"diabetes, triglyceride, dyslipidemia, Xuezhikang, Cardiovascular risk","lastPublishedDoi":"10.21203/rs.3.rs-871652/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-871652/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003cp\u003e\u003cstrong\u003eBackground:\u003c/strong\u003e Diabetes often accompanies with increase in triglyceride(TG) as well as small dense low density lipoprotein(sdLDL). Statins are difficult to completely correct this dyslipidemia. Xuezhikang, an extract of cholestin, is better than some statins in reducing TG. Under the condition of the similar decrease in LDL-cholesterol (LDL-C), it is not clear whether there is any difference in the effect of XZK and statins on TG reduction in patients with Type 2 DM(T2DM). \u003c/p\u003e\u003cp\u003e\u003cstrong\u003eMethods:\u003c/strong\u003e An open-label multicenter study is planned to estimate the effects of Xuezhikang(1.2 g/d) and pravastatin(20 mg/d) on TG level and other blood lipids in T2DM patients with dyslipidemia and moderate to high risk of cardiovascular diseases. A total of 114 patients will be enrolled and randomly assigned (1:1 ratio) to accept Xuezhikang or pravastatin therapy for 6 weeks. The primary outcome measure is the change in fasting TG level after 6 weeks. The changes in other fasting lipids and postprandial lipids at 1, 2, 4 h after a nutritious breakfast will also be explored. The planned duration for enrollment is between November 2021 and December 2022. \u003c/p\u003e\u003cp\u003e\u003cstrong\u003eConclusion:\u003c/strong\u003e This study will evaluate the effect of 6-week treatment of Xuezhikang(1.2 g/d) and pravastatin(20 mg/d) on fasting TG level and other blood lipids in T2DM patients with dyslipidemia, which may provide a more optimized schedule for lipid control in patients with diabetes and dyslipidemia in primary prevention.\u003c/p\u003e","manuscriptTitle":"Effects of Xuezhikang vs. Pravastatin on Triglyceride Level in Patients with Type 2 Diabetes Mellitus and Dyslipidemia: A Research Protocol for a Randomized Controlled Study","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2021-09-14 16:18:45","doi":"10.21203/rs.3.rs-871652/v1","editorialEvents":[{"type":"communityComments","content":0}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"017a0bc0-20d5-44fb-ba5d-cea81c8c0263","owner":[],"postedDate":"September 14th, 2021","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"posted","subjectAreas":[{"id":7167571,"name":"Cardiac \u0026 Cardiovascular Systems"},{"id":7167572,"name":"Endocrinology \u0026 Metabolism"}],"tags":[],"updatedAt":"2021-09-14T16:18:46+00:00","versionOfRecord":[],"versionCreatedAt":"2021-09-14 16:18:45","video":"","vorDoi":"","vorDoiUrl":"","workflowStages":[]},"version":"v1","identity":"rs-871652","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-871652","identity":"rs-871652","version":["v1"]},"buildId":"7rjqhiLT3MXkJMwkYKINL","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}